Supporting this, the anti-VEGF inhibitor bevacizumab reduces epistaxis and high-output heart failure in HHT patients with hepatic AVMs (Dupuis-Girod et al., 2012). This evidence concerns the gene VEGFA and hereditary hemorrhagic telangiectasia.